相关实验视频
Updated: Jul 7, 2025
07:37
An Adoptive Transfer Model of Rheumatoid Arthritis in Mice
Published on: June 6, 2025
125
在类风湿性关节炎相关的间歇性肺部疾病中使用抗纤维素剂:系统性审查和元分析
Ji Hoon Jang1, Junghae Ko2, So Young Jung3
1Division of Pulmonology and Critical Care Medicine, Department of Internal Medicine, Haeundae Paik Hospital, Inje University College of Medicine, Busan 48108, Republic of Korea.
Life (Basel, Switzerland)
|December 23, 2023
概括
尼丁达尼布和皮尔芬尼等抗纤维素药物显著降低了风湿关节炎相关的间歇性肺病 (RA-ILD) 患者的肺功能下降. 这一元分析证实了它们在RA-ILD中减缓疾病进展的潜力.
科学领域:
- 肺部病理学 肺部病理学
- 类风湿病学 类风湿病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 类风湿关节炎相关的间歇性肺病 (RA-ILD) 是类风湿关节炎 (RA) 的严重并发症.
- 目前,RA-ILD没有确定的治疗方法,影响患者的发病率和死亡率.
- 抗纤维素药物正在研究其潜在的治疗效果.
研究的目的:
- 进行一项元分析,评估RA-ILD患者抗纤维素药物的疗效.
- 确认宁泰达尼布和皮尔芬尼对RA-ILD疾病进展的临床影响.
主要方法:
- 在多个数据库 (Ovid MEDLIVE,Cochrane Library,EMBASE,KoreaMed) 中进行了系统的文献搜索.
- 包括两个随机对照研究,比较成年RA-ILD患者的宁泰达尼布或皮尔芬尼与安慰剂.
- 评估的主要结局是强迫生命能力 (FVC) 的变化和52周内预测FVC增加≥10%的患者比例.
主要成果:
- 两项研究的元分析显示,与安慰剂相比,抗纤维素药物显著降低了FVC下降 (平均差异:88.30).
- 与安慰剂相比,抗纤维素剂组中较少的患者在预测的FVC中经历了≥10%的增加 (几率比:0.42,p=0.04).
- 在包括的研究之间没有观察到显著的异质性 (I2 = 0%).
结论:
- 丁丁达尼布和皮尔芬尼在缓解RA-ILD患者疾病进展方面显示出临床效用.
- 这些发现表明抗纤维素药物可能是RA-ILD的可行的治疗选择.
- 需要进一步的研究来巩固RA-ILD中抗纤维素剂的临床益处.
相关概念视频
01:17Drugs Used in Lower Respiratory Disorders: Overview
449
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
449
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
141
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
141
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
168
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
168
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
187
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
187
01:19Antiasthma Drugs: Leukotriene Modifiers
315
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
315
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
436
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
436